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Abstract 
Background: Breast cancer (BrC) remains the leading cause of cancer‑related death in women, mainly due to 
recurrent and/or metastatic events, entailing the need for biomarkers predictive of progression to advanced disease. 
MicroRNAs hold promise as noninvasive cancer biomarkers due to their inherent stability and resilience in tissues 
and bodily fluids. There is increasing evidence that specific microRNAs play a functional role at different steps of the 
metastatic cascade, behaving as signaling mediators to enable the colonization of a specific organ. Herein, we aimed 
to evaluate the biomarker performance of microRNAs previously reported as associated with prognosis for predicting 
BrC progression in liquid biopsies.
Methods: Selected microRNAs were assessed using a quantitative reverse transcription‑polymerase chain reaction 
in a testing cohort of formalin‑fixed paraffin‑embedded primary (n = 16) and metastatic BrC tissues (n = 22). Then, 
miR‑30b‑5p and miR‑200b‑3p were assessed in a validation cohort #1 of formalin‑fixed paraffin‑embedded primary 
(n = 82) and metastatic BrC tissues (n = 93), whereas only miR‑30b‑5p was validated on a validation cohort #2 of liquid 
biopsies from BrC patients with localized (n = 20) and advanced (n = 25) disease. ROC curve was constructed to evalu‑
ate prognostic performance.
Results: MiR‑30b‑5p was differentially expressed in primary tumors and paired metastatic lesions, with bone metas‑
tases displaying significantly higher miR‑30b‑5p expression levels, paralleling the corresponding primary tumors. 
Interestingly, patients with advanced disease disclosed increased circulating miR‑30b‑5p expression compared to 
patients with localized BrC.
Conclusions: MiR‑30b‑5p might identify BrC patients at higher risk of disease progression, thus, providing a useful 
clinical tool for patients’ monitoring, entailing earlier and more effective treatment. Nonetheless, validation in larger 
multicentric cohorts is mandatory to confirm these findings.
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Background
Breast cancer (BrC) is the second most frequent cancer 
worldwide and the most commonly diagnosed cancer 
among women [1]. Despite improvements in early detec-
tion and treatment, BrC remains the leading cause of 
cancer-related death in women, mainly due to the devel-
opment of recurrent and/or metastatic disease [1, 2]. In 
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distant metastases and up to 10–15% of patients develop 
distant metastases within the first 3 years [3].
Metastatic BrC arises following the proliferation and 
dissemination of malignant cells from its primary loca-
tion to distant organs [4]. Metastases often display an 
organ-specific pattern of spread, with bone constitut-
ing the most common site for BrC, followed by lungs, 
liver, and brain [3]. The development of metastases is the 
major prognostic factor for BrC patients, as metastatic 
BrC is incurable in most cases [5]. Thus, adequate patient 
monitoring, using minimally invasive biomarkers, that 
might anticipate the diagnosis of progressing disease, 
might allow for earlier implementation of adequate ther-
apy, improving BrC patients’ survival and quality of life.
MicroRNAs (miRNAs) are endogenous, highly con-
served small non-coding RNAs of approximately 22 
nucleotides in length involved in genes’ posttranscrip-
tional regulation [6]. Recently, the value of miRNAs as 
cancer biomarkers has been emphasized, emerging as 
promising diagnostic, prognostic and predictive bio-
markers for BrC [7], including advanced BrC [8, 9]. 
Moreover, several lines of evidence implicate miRNAs 
either as promotors or suppressors of BrC metastization, 
by targeting multiple signaling pathways and important 
proteins that are major players at different steps of the 
metastatic process [8, 9].
Specifically, the role of miR-200 family (miR-200f) 
members in the initial steps of the metastatic cascade, by 
regulating ZEB1 and ZEB2 expression and consequently 
the E-cadherin expression has been described by sev-
eral groups [10, 11]. Likewise, the miR-30 family (miR-
30f ) members have been previously reported to promote 
tumor invasion and metastases formation in melanomas 
[12], whereas in BrC downregulation was implicated in 
the metastatic process [13, 14]. Conversely, miR-182-5p 
upregulation was associated with epithelial-like state in 
BrC cell lines and macrometastases formation in  vivo 
[15].
Nonetheless, we have previously shown that miR-
30b-5p, miR-30c-5p, miR-182-5p and miR-200b-3p 
expression levels associated with patients prognosis in 
luminal BrC [16].
Thus, we set out a study aiming to assess the biomarker 
potential of the previously identified miRNAs expression 




Formalin-fixed paraffin-embedded (FFPE) primary and 
metastatic tumors available from BrC patients were 
included in this study: 16 patients for the testing cohort 
and 82 for the validation cohort #1. Sixteen primary BrC 
and 22 paired metastases were obtained from the test-
ing cohort and 82 primary BrC and 93 paired metastases 
were obtained from the validation cohort #1. Relevant 
clinical data were retrieved from the patients’ charts. All 
cases were revised by an experienced pathologist, clas-
sified according to the most recent 4th edition World 
Health Organization (WHO) classification, graded 
according to Bloom and Richardson’s Modified system 
and staged according to the 7th edition American Joint 
Committee on Cancer (AJCC) system [17, 18]. Four μm 
sections were cut from each tissue block and stained with 
hematoxylin–eosin, which were examined by the pathol-
ogist to select the most representative tumor lesion. 
Tumor areas identified were then macrodissected in 6 
consecutive 8  µm sections for tumor cells enrichment 
(> 80%).
Additionally, peripheral blood samples from 20 patients 
with localized BrC and 25 patients with advanced BrC 
were collected at the Portuguese Oncology Institute of 
Porto (IPO Porto) after informed patient consent (vali-
dation cohort #2). Briefly, peripheral blood was collected 
into EDTA-containing tubes and centrifuged at 2000 rpm 
for 10 min at 4 °C. Plasma was immediately separated, ali-
quoted into 1.5 mL tubes and properly stored at − 80 °C 
until further use.
This study was approved by the institutional eth-
ics committee (Comissão de Ética para a Saúde, CES-
IPOFG-EPE 019/08 and CES 120/015) and sample 
collection was performed in accordance with the Decla-
ration of Helsinki. Informed consent was obtained from 
all individual participants included in the study.
RNA extraction
RNA extraction from FFPE tissues was performed using 
a commercially available extraction kit (FFPE RNA/DNA 
Purification Plus Kit, Norgen Biotek, Thorold, Canada) in 
accordance with manufacturer’s instructions. Circulating 
RNA from plasma samples was obtained using miRNeasy 
Serum/Plasma Kit (Qiagen, Hilden, Germany), accord-
ing to manufacturer’s protocol. RNA concentrations and 
purity ratios were ascertained using NanoDrop Lite spec-
trophotometer (NanoDrop Technologies, Wilmington, 
DE, USA) and RNA samples were stored at − 80 °C.
MicroRNAs’ cDNA synthesis
The cDNA synthesis from FFPE tissues RNA was per-
formed in a  Veriti® Thermal Cycler (Applied Biosystems, 
Foster City, CA, USA) using miRCURY LNA™ Universal 
RT microRNA PCR (Exiqon, Vedbaek, Denmark) follow-
ing manufacturer’s instructions. Circulating RNA was 
reverse transcribed to cDNA using TaqMan Advanced 
miRNA cDNA synthesis kit (Applied Biosystems, Foster 
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City, CA, USA). All cDNA samples were then stored at 
− 20 °C.
Real‑time quantification of microRNA
For the detection of cDNA derived from tissue samples, 
per each well, it was added: 5  μL of Xpert Fast SYBR 
(2X) (GRiSP, Porto, Portugal), 1  μL of miRNA specific 
primer mix (microRNA LNA™ PCR primer set, Exiqon, 
Vedbaek, Denmark), in accordance with manufacturer’s 
protocol, and 4 μL of previously diluted (20X) cDNA. For 
detection of cDNA derived from circulating miRNAs, 
per each well, it was added: 5 μL of Xpert Fast Probe (2X) 
(GRiSP, Porto, Portugal), 0.5  μL of  TaqMan® Advanced 
miRNA Assay (20X) (Applied Biosystems, Foster City, 
CA, USA) and 4.5 μL of diluted cDNA.
Quantitative real-time PCR (RT-qPCR) reactions were 
performed in 384-well plates. Each amplification reaction 
was performed in triplicate on a LightCycler 480 instru-
ment (Roche Diagnostics, Manheim, Germany). Each 
plate also contained two negative template controls.
For the intercalating green dye chemistry, RT-qPCR 
protocol consisted of a denaturation step at 95  °C for 
2 min, followed by 40 amplification cycles at 95 °C for 5 s 
and 60 °C for 20 s. Melting curve analysis was performed 
according to instrument’s manufacturer recommenda-
tions. For the probe-detection technology, RT-qPCR pro-
tocol consisted of a denaturation step at 95 °C for 3 min, 
followed by 45 amplification cycles at 95 °C for 10 s and 
60 °C for 25 s.
SNORD38B was used as a reference gene for nor-
malization as previously reported [16]. The relative 
miRNA expression in each tissue RNA sample was cal-
culated using the  2−ΔCT method: (Relative miRNA 
expression = 2−ΔCt, in which ΔCt = Ct target miRNA − 
 Ctreference) × 1000, whereas for liquid biopsies, relative 
miRNA expression was calculated using the formula: 
(Mean quantity of target miRNA/Mean quantity of 
SNORD38B) × 1000. Five serial 10 × dilutions of posi-
tive control were run in each plate to generate a standard 
curve. All plates had an efficiency between 90 and 100%. 
The target sequences of mature miRNAs analyzed are 
provided in Additional file 1: Table S1.
Statistical analysis
Non-parametric Mann–Whitney U test and Kruskal–
Wallis test, followed by Mann–Whitney U tests when 
appropriate, were used to ascertain the statistical signifi-
cance of differences in continuous variables among two 
or more independent datasets, respectively. Bonferroni 
correction was applied to pairwise comparisons. Dif-
ferences between paired samples were analyzed using 
the non-parametric Wilcoxon paired sample test. Fold 
changes for miRNA were calculated using the  2−ΔΔCT 
method [19]. Spearman non-parametric test was per-
formed to assess the correlation between continuous 
variables.
Receiver Operating Characteristic (ROC) curve was 
constructed and biomarker performance parameters 
(sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and accuracy) were cal-
culated. The cut-off was established based on the high-
est value obtained in ROC curve analysis according to 
Youden’s J index [20, 21].
Statistical analysis was performed using SPSS software 
(SPSS Version 24.0, Chicago, IL) and two-tailed p-values 
were considered statistically significant when p < 0.05. 
Graphs were built using GraphPad 6 Prism (GraphPad 
Software, USA).
Results
Evaluation of miRNAs expression in FFPE BrC patients’ 
testing cohort
MiR-30b-5p, miR-30c-5p, miR-182-5p and miR-200b-3p 
expression levels were assessed in FFPE tissues from 
the testing cohort. Four of the 16 patients had multiple 
metastases at different sites (Additional file 1: Table S2). 
The time between diagnosis of the primary tumor and 
metastasis varied from 1.51 to 20.43  years (median 
7.27 years).
MiR-30b-5p and miR-200b-3p expression levels were 
significantly higher in metastatic lesions versus matched 
primary tumors (p = 0.007 and p = 0.009, respectively, 
Fig.  1a, b). Furthermore, miR-30b-5p and miR-200b-3p 
expression levels were significantly higher in metastatic 
lesions, in 10 of 16 patients and in 11 of 16 patients, 
respectively, both with a fold variation higher than 1. No 
significant expression differences were found between 
primary tumors and the corresponding metastatic lesions 
for the remain miRNAs.
MiR‑30b‑5p and miR‑200b‑3p expression levels in cohort 
#1 and association with clinicopathological features
MiR-30b-5p and miR-200b-3p were further tested in a 
larger set of 175 tumor samples (validation cohort #1, 
Table  1 and Additional file  1: Table  S3). Among the 93 
available metastases, 63 were from bone, 17 from lung, 4 
from brain and 9 were locoregional or from the contralat-
eral breast. It should be noted that 10 patients had multi-
ple metastases with different locations (Additional file 1: 
Table  S3). Overall, the time elapsed between diagnosis 
of the primary tumor and metastasis varied from 0.15 to 
18.98 years (median 6.63 years).
MiR-30b-5p expression levels were significantly higher 
in metastases than in primary tumors (p < 0.001, Fig. 2), 
confirming the findings obtained in the above-men-
tioned testing cohort. Interestingly, primary tumors that 
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metastasized to bone disclosed significantly higher miR-
30b-5p expression levels compared to all other primary 
tumors (p = 0.002, Fig.  3a). Moreover, bone metastases 
displayed significantly higher miR-30b-5p expression lev-
els than all samples from other metastatic sites (p < 0.001, 
Fig. 3b).
Except for human epidermal growth factor 2 recep-
tor (HER2) status, no statistically significant associa-
tions were found between miR-30b-5p expression levels 
and any of the clinicopathological parameters (age, his-
tological type, grade, TNM staging, molecular subtype 
assessed by immunohistochemistry, estrogen receptor 
(ER) and progesterone receptor (PR) status). Indeed, 
HER2-negative tumors depicted significantly higher miR-
30b-5p expression levels compared to HER2-positive BrC 
(p = 0.041).
The same analysis was performed for miR-200b-3p’s 
expression levels, however, no statistical differences were 
observed between primary tumors and matched metasta-
ses neither significant associations were found with clin-
icopathological parameters.
Assessment of miR‑30b‑5p expression as prognostic 
biomarker in liquid biopsies (validation cohort #2)
A BrC patient cohort composed of 20 patients with local-
ized BrC (stage I) and 25 patients with advanced BrC, 
comprising both locally advanced (n = 13) and metastatic 
BrC (n = 12) was used for validation of miR-30b-5p in 
liquid biopsies (validation cohort #2, Table  2). No sig-
nificant differences were found for patients’ age between 
localized and advanced BrC (p = 0.417).
Remarkably, patients with locally advanced (stage 
III) and patients with metastatic BrC (stage IV) dis-
played higher circulating miR-30b-5p expression lev-
els compared to localized BrC (p = 0.003 and p = 0.003, 
respectively, Fig.  4a). Moreover, advanced BrC group 
comprising patients with locally advanced and meta-
static disease presented significantly higher circulating 
miR-30b-5p levels than patients with localized disease 
(p < 0.001; Fig. 4b).
Accordingly, circulating miR-30b-5p levels were sig-
nificantly higher in patients with T2 tumors and grade 
2 tumors (p = 0.018 and p = 0.012, respectively) and in 
patients with positive axillary lymph nodes and metas-
tases at the time of diagnosis (p < 0.001, Fig.  4c and 
p = 0.015, Fig. 4d, respectively). No significant differences 
were observed for miR-30b-5p circulating levels and any 
of the clinicopathological parameters (age, histological 
type, molecular subtype assessed by immunohistochem-
istry, HER2, ER, and PR status).
ROC analysis revealed that circulating miR-30b-5p 
expression levels could discriminate advanced from local-
ized BrC patients with an area under the curve (AUC) of 
0.831 (95% CI 0.721–0.950). Using a cut-off value of 4611, 
circulating miR-30b-5p expression identified advanced 
disease with 88.9% sensitivity, 66.7% specificity, 75.6% 
accuracy, 64.0% PPV and 90.0% NPV (Fig. 5).
Discussion
BrC remains the most common malignancy in women 
and a major cause of morbidity and mortality [1]. 
Although biological features are routinely used for BrC 
diagnosis and prognosis assessment, patients with similar 
clinicopathological features often show different clinical 
outcomes [22]. Therefore, identification of biomarkers 
providing more accurate prognostic information for BrC 
patients, complementing currently used parameters, will 
have a major impact. Consequently, assessment of spe-
cific miRNAs expression deregulation, which has been 
associated with several mechanisms underlying BrC 
aggressiveness, might be a potential source for biomark-
ers [7, 23]. Most studies addressing miRNAs expression 
Fig. 1 MiR‑30b‑5p (a) and miR‑200b‑3p (b) relative expression levels in primary tumors and the corresponding paired metastases. ** p value < 0.01 
by non‑parametric Wilcoxon paired sample test. Y‑axis denotes  2−ΔCT values multiplied by 1000
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and miRNA-target validation have been performed in 
cancer cell lines lacking tumor-host interactions [7, 24]. 
Thus, tissue analysis might allow for a broader insight 
into biologically and clinically relevant miRNAs which 
may serve as prognostic biomarkers.
In previous work, we reported a panel of miRNAs 
related to luminal BrC patients’ prognosis, suggesting 
these miRNAs as potential progression biomarkers [16]. 
Hence, we aimed to evaluate the biomarker potential of 
miR-30b-5p, miR-30c-5p, miR-182-5p and miR-200b-3p 
for progression/metastization in BrC.
In the testing cohort, only miR-30b-5p and miR-
200b-3p expression were significantly higher in meta-
static lesions compared to matched primary BrC tissues. 
Although increased miR-182-5p expression levels have 
previously been detected in paired metastatic lymph 
nodes when compared with primary tumors [15], we 
were not able to confirm the same in our testing set of 
BrC tissues. This might be due to the small number of 
samples, the restricted molecular subtype of the primary 
tumor and the variability of metastases localization.
MiR-30b-5p and miR-200b-3p were further evaluated 
in a larger set of tumor tissue samples from BrC patients 
(validation cohort #1). It should be recalled that the sta-
bility of miRNAs in FFPE tissues holds an enormous 
potential [25], especially in BrC patients in which late 
relapses frequently occur, as demonstrated in the test-
ing cohort and validation cohort #1. Herein, miR-30b-5p 
expression levels were found to be significantly higher 
in metastatic lesions compared to matched primary BrC 
tissues in the validation cohort #1, despite the patients 
studied are mostly luminal, and the rather limited num-
ber of non-bone metastases. Although downregulation 
Table 1 Breast cancer patients’ clinicopathological data 
of the testing and validation cohort #1
ER estrogen receptor, G grade, HER2 human epidermal growth factor receptor 2, 
NST no special type, PR progesterone receptor
a Assessed by immunohistochemistry
Clinicopathological features Testing cohort Validation cohort #1
Patients (n) 16 82
Age median (range) 58 (35–78) 49 (28–76)
Molecular  subtypea (%)
 Luminal A‑Like 4 (25.0) 19 (23.2)
 Luminal B‑Like 12 (75.0) 58 (70.7)
 HER2‑enriched – 1 (1.2)
 Basal‑like/TNBC – 4 (4.9)
Histological type (%)
 Invasive carcinoma of NST 13 (81.2) 73 (89.0)
 Invasive lobular carcinoma 3 (18.8) –
 Other special subtype carci‑
noma
– –
 Mixed type carcinoma – 9 (11.0)
Grade (%)
 G1 2 (12.5) 4 (4.9)
 G2 4 (25.0) 43 (52.4)
 G3 8 (50.0) 35 (42.7)
 Gx 2 (12.5) –
ER receptor status (%)
 Positive 16 (100.0) 77 (93.9)
 Negative – 5 (6.1)
PR receptor status (%)
 Positive 10 (62.5) 65 (79.3)
 Negative 6 (37.5) 17 (20.7)
HER2 receptor status (%)
 Positive 3 (18.8) 15 (18.3)
 Negative 13 (81.2) 67 (81.7)
T Stage (%)
 T1 4 (25.0) 20 (24.4)
 T2 9 (56.2) 52 (63.4)
 T3 1 (6.3) 5 (6.1)
 T4 2 (12.5) 3 (3.7)
 Tx – 2 (2.4)
N Stage (%)
 N0 5 (31.2) 18 (22.0)
 N1 7 (43.8) 33 (40.2)
 N2 2 (12.5) 16 (19.5)
 N3 2 (12.5) 13 (15.9)
 Nx – 2 (2.4)
Stage (%)
 I 3 (18.8) 10 (12.2)
 II 8 (50.0) 34 (41.5)
 III 5 (31.2) 24 (29.3)
 IV – 12 (14.6)
 Not determined – 2 (2.4)
Fig. 2 MiR‑30b‑5p relative expression levels in primary tumors 
and the corresponding matched metastases. *** p‑value < 0.001 by 
non‑parametric Wilcoxon paired sample test. Y‑axis denotes  2−ΔCT 
values multiplied by 1000
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of miR-30f members and its role as tumor suppressor 
during BrC invasion and metastization have been previ-
ously reported [13, 14], miR-30b-5p upregulation in BrC 
metastatic tissue samples has not been described thus 
far. The role of miR-30b-5p remains controversial. On 
one hand, expression of miR-30b-5p and miR-30c-5p has 
been associated with increased cell viability and resist-
ance to apoptosis [26], and miR-30b-5p was found to be 
upregulated in several cancers [27–29] and associated 
with metastases in melanoma [12]. On the other hand, 
miR-30b-5p was also associated with decreased migra-
tion and invasiveness in colorectal cancer [30, 31], and 
miR-30a was reported to be downregulated in primary 
nasopharyngeal carcinoma tissues but overexpressed 
in the corresponding metastases [32], although miR-30f 
members were shown to inhibit early steps of the meta-
static process [33]. Our data clearly support an oncogenic 
role for miR-30b-5p in BrC.
Progression of solid malignancies is the result of a 
multi-step cascade in which tumor cells undergo wide-
spread modifications to successfully migrate and colonize 
other organs. In this process, the dynamic ability to first 
undergo epithelial-to-mesenchymal transition (EMT) 
and subsequently mesenchymal-to-epithelial transition 
(MET) is an important feature of metastatic cells [34]. 
In support of the MET hypothesis, several studies have 
shown that metastatic lesions and the corresponding pri-
mary breast tumor have a similar epithelial nature [35, 
36]. MiR-30b-5p modulation might be important in this 
plastic process. Downregulation of miR-30f members 
might lead to EMT initiation enabling cells to metasta-
size, while subsequent upregulation might be associated 
with MET, facilitating re-adaptation of the epithelial 
phenotype and colonization, crucial to develop macro-
scopic metastases. In fact, a recent study showed that 
downregulation of miR-30f members in primary BrC of 
patients without evidence of distant metastases was asso-
ciated with poor relapse-free survival, which might be 
associated with the ability of decreased miR-30f levels 
to prompt EMT initiation. However, miR-30f expression 
levels were only evaluated in primary BrC tissue and were 
not assessed in metastatic lesions. Nevertheless, Kenny 
et al. [37] classified BrC cell lines into four morphologi-
cal categories. BT-474 cell line, derived from a primary 
BrC, was included in Mass category characterized by 
tightly cohesive colonies with strong cell–cell adhesion, 
whereas MDA-MB-231, a metastatic cell line derived 
from a pleural effusion, was allocated to Stellate category 
characterized by limited cell–cell interactions and lacked 
E-cadherin expression, which are characteristics of EMT. 
Thus, these different phenotypes are in agreement with 
the previous hypothesis that decreased miR-30b-5p 
expression levels might lead to EMT initiation enabling 
cells with motility and invasive features. This might 
explain lower miR-30b-5p expression in MDA-MB-231 
cells, and subsequent upregulation associated with MET, 
enabling re-adaptation of the epithelial phenotype, which 
was observed in BT-474 cells. Therefore, additional stud-
ies are needed to ascertain the miR-30b-5p functional 
role in BrC and the downstream transcriptional gene tar-
gets that might mediate distant metastases.
Knowledge of determining patterns of metastatic organ 
tropism might provide useful information for clinical 
evaluation of disease stage and to monitor progression. 
Hence, comparative analyses of miR-30b-5p expression 
according to the metastatic site were performed. Inter-
estingly, bone metastases disclosed significantly higher 
miR-30b-5p expression levels compared to other metas-
tases and, remarkably, primary BrC cases that metasta-
sized to bone also displayed increased levels compared to 
those that did not. These results strongly suggest that not 
only miR-30b-5p plays a role in metastization, but it also 
Fig. 3 Scatter‑plots of miR‑30b‑5p relative expression in primary tumors (a) and metastases (b). ** p‑value < 0.01 and *** p‑value < 0.001 by 
non‑parametric Mann–Whitney U test. Y‑axis denotes  2−ΔCT values multiplied by 1000
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predisposes tumor cells to home at specific organ sites, 
especially promoting bone colonization by tumor cells. 
Nevertheless, it should be recalled that miRNAs expres-
sion is highly context- and tissue-dependent, and thus, 
ideally, miRNA expression in normal tissues more prone 
to receive metastatic cells should also be assessed. We 
could then ascertain whether differential expression of 
miRNAs in the primary tumors versus metastatic tissues 
might be a consequence of their modulation in the meta-
static microenvironment. Moreover, the mechanisms 
underlying tumor cell tropism to the bone and the extent 
to which metastatic cells miRNA’s profile differ according 
to their location may add valuable insights into disease 
development and clinical management. In fact, miR-30f 
members were reported to inhibit BrC bone metasta-
ses in an experimental model [38]. Nevertheless, these 
results were derived from triple negative BrC cell lines, 
which represent a (very) limited subset of BrC patients 
who do not commonly develop bone metastases. None-
theless, it is well-recognized that BrC patients prone to 
develop bone metastases are mainly those which dis-
play luminal features [39, 40], and, thus this experimen-
tal model can hardly be considered representative of the 
clinically apparent heterogeneity.
Circulating miRNAs are stable in body fluids and their 
assessment might provide valuable diagnostic, prognos-
tic and therapeutic prediction information, allowing for 
noninvasive testing and potential individual treatment 
optimization [7]. Recently, miR-30b-5p expression lev-
els were shown to distinguish BrC patients from healthy 
controls in liquid biopsies [41], although miR-30b-5p 
expression levels have also been associated with aged 
[42]. Remarkably, we found that miR-30b-5p could dis-
criminate patients with advanced BrC from those with 
localized BrC with high sensitivity, but modest specific-
ity and overall accuracy, and no association with age was 
disclosed. Although the limited size of cohort #2 should 
be acknowledged, our results suggest that miR-30b-5p 
might identify, at diagnosis, patients who are more likely 
to endure disease progression. Particularly, circulating 
miR-30b-5p levels might provide a useful tool for early 
detection of BrC metastases, if these findings are further 
proven in a larger set of patients.
Several other miRNAs have been implicated in BrC 
invasion and metastasis [7]. MiR-10b was found highly 
expressed in tissue samples from patients with metastatic 
BrC [43] and, more recently, found to be significantly 
more expressed in tissues from patients with stage III 
and IV BrC compared to early-stage disease [44]. Moreo-
ver, circulating miR-10b combined with miR-373 might 
identify BrC lymph node metastasis with 72% sensitiv-
ity and 94.3% specificity [45], and miR-21 overexpression 
was significantly correlated with lymph node metastases, 
advanced clinical stage and poor prognosis [46]. Not-
withstanding the tissue series size (n = 113), no stage 
IV patients were included in this study [46]. Similarly, 
circulating miR-21 discriminated stage IV BrC patients 
Table 2 Clinicopathological data of breast cancer patients 
of validation cohort #2
BrC breast cancer, ER estrogen receptor, G grade, HER2 human epidermal growth 
factor receptor 2, n.a. not applicable, NST no special type, PR progesterone 
receptor
a Assessed by immunohistochemistry
Clinicopathological features Localized BrC Advanced BrC
Patients (n) 20 25
Age median (range) 61 (39–71) 53 (35–82)
Molecular  subtypea (%)
 Luminal A‑Like 7 (35.0) 2 (8.0)
 Luminal B‑Like 13 (65.0) 16 (64.0)
 HER2‑enriched – 5 (20.0)
 Basal‑like – 2 (8.0)
Histological type (%)
 Invasive carcinoma of NST 17 (85.0) 18 (72.0)
 Invasive lobular carcinoma 2 (10.0) 4 (16.0)
 Other special subtype carcinoma – 2 (8.0)
 Mixed type carcinoma 1 (5.0) 1 (4.0)
Grade (%)
 G1 4 (20.0) –
 G2 9 (45.0) 19 (76.0)
 G3 7 (35.0) 6 (24.0)
ER receptor status (%)
 Positive 20 (100.0) 18 (72.0)
 Negative – 7 (28.0)
PR receptor status (%)
 Positive 20 (100.0) 14 (56.0)
 Negative – 11 (44.0)
HER2 receptor status (%)
 Positive 4 (20.0) 11 (44.0)
 Negative 16 (80.0) 14 (56.0)
T Stage (%)
 T1 20 (100.0) 3 (12.0)
 T2 – 11 (44.0)
 T3 – 5 (20.0)
 T4 – 6 (24.0)
N Stage (%)
 N0 20 (100.0) –
 N1 – 4 (16.0)
 N2 – –
 N3 – 20 (80.0)
 Nx – 1 (4.0)
Stage (%)
 IA 20 (100.0) n.a.
 IIIC n.a. 13 (52.0)
 IV n.a. 12 (48.0)
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with visceral metastasis from those with stage I, II and 
III disease, with 86% specificity and 70% sensitivity [47]. 
Nonetheless, as far as we know, these metastasis-related 
miRNAs were only evaluated in primary BrC tissue and 
were not assessed in a larger tissue series of primary 
tumors and the corresponding metastatic lesions. Of 
note, in our study, circulating miR-30b-5p expression 
levels identified advanced disease with higher sensitivity, 
although with limited specificity.
Conclusions
Our results indicate that miR-30b-5p is overexpressed in 
metastatic BrC, suggesting an important role in tumor 
dissemination. Interestingly, bone metastases and their 
correspondent primary tumors displayed higher miR-
30b-5p expression levels, suggesting a role in modulation 
of metastatic organ tropism. Importantly, advanced BrC 
Fig. 4 Scatter‑plot of circulating miR‑30b‑5p relative expression according to stage (a). ** p‑value < 0.01 by non‑parametric Kruskal–Wallis test. 
Y‑axis denotes circulating miR‑30b‑5p relative expression multiplied by 1000. Scatter‑plots of circulating miR‑30b‑5p relative expression in localized 
and advanced breast cancer (b) and according to N stage (c) and M stage (d). * p‑value < 0.05 and *** p‑value < 0.001 by non‑parametric Mann–
Whitney U test. Y‑axis denotes circulating miR‑30b‑5p relative expression multiplied by 1000
Fig. 5 ROC curve analysis to evaluate the potential of miR‑30b‑5p 
as a biomarker for discriminate patients with advanced breast cancer 
from patients with localized breast cancer
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patients disclosed significantly higher circulating miR-
30b-5p expression levels compared to patients with local-
ized BrC, suggesting that circulating miR-30b-5p levels 
might identify BrC patients at higher risk of disease pro-
gression, providing a useful clinical tool for patient moni-
toring, entailing earlier and more effective treatment. 
Nonetheless, validation in larger multicentric cohorts is 
needed to further sustain our findings.
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